Pharmaceuticals
-
Banks & Payments
Glenmark’s $15.3M Settlement: A New Chapter in Generic-Drug Price Fixing Scrutiny?
Glenmark Pharmaceuticals Ltd.’s U.S. unit has agreed to pay approximately $15.3 million to Humana Inc., resolving significant antitrust claims linked…
Read More » -
Politics & Policy
Hims & Hers Eyes Compounded Peptides: A Regulatory Tightrope?
Hims & Hers, a prominent telehealth provider, is reportedly setting its sights on the potentially lucrative, yet complex, market of…
Read More » -
Investing & Wealth
Bristol Myers Manufacturing: A $2.3 Billion Bet on Future Therapy?
Bristol Myers Squibb‘s recent announcement to construct a biopharmaceutical manufacturing site in Houston, a substantial $2.3 billion investment, signals a…
Read More » -
Insurance & Protection
Pharma’s Shifting Sands: How Biosimilars and IRA Pricing Impact Drug Spend
Amgen’s second-quarter 2026 financial outcomes provide a compelling snapshot of a pharmaceutical market undergoing significant transformation, primarily driven by the…
Read More » -
Investing & Wealth
Eli Lilly’s Bold Move: Early Access to Next-Gen Obesity Drug?
Eli Lilly‘s decision to grant early access to its next-gen obesity drug marks a significant moment in the battle against…
Read More » -
Banks & Payments
AstraZeneca Bristol Myers Merger: A $400 Billion Antitrust Challenge?
Early discussions regarding a potential AstraZeneca Bristol Myers merger have sent ripples through the pharmaceutical industry, signaling a transaction that…
Read More » -
Investing & Wealth
Novo Nordisk’s Q2 Triumph: What Does a Raised Outlook Signify?
The latest financial disclosures from Novo Nordisk reveal a significantly bolstered financial position, with the company’s Q2 profit decisively beating…
Read More » -
Investing & Wealth
AstraZeneca and Bristol Myers Squibb: A $400 Billion Megadeal Looming?
Reports indicate discussions between pharmaceutical giants AstraZeneca and Bristol Myers Squibb regarding a staggering pharmaceutical megadeal valued at $400 billion.…
Read More » -
Investing & Wealth
Can $750 Million Reshape US Drug Manufacturing Resilience?
Eli Lilly and National Resilience are set to infuse $750 million into expanding **US drug manufacturing** capabilities, a strategic move…
Read More » -
Politics & Policy
Generic Drug Tariffs: A Looming Threat to Healthcare Costs?
The prospect of a 100 percent generic drug tariffs beginning in 2028 presents a significant potential upheaval for the pharmaceutical…
Read More »
